Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: Cagrilintide: Benefits, Dosage, and Weight Loss Potential Explained Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide Elive Health & Wellness Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet